"Ifosfamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
- Iso Endoxan
- NSC 109,724
- NSC 109724
Below are MeSH descriptors whose meaning is more general than "Ifosfamide".
Below are MeSH descriptors whose meaning is more specific than "Ifosfamide".
This graph shows the total number of publications written about "Ifosfamide" by people in this website by year, and whether "Ifosfamide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Ifosfamide" by people in Profiles.
Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile. Support Care Cancer. 2022 Mar; 30(3):2755-2766.
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015; 56(9):2569-78.
Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): a phase II randomised study by the European Lung Cancer Working Party. Lung Cancer. 2012 Sep; 77(3):605-10.
Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res. 2010 Jan; 48(1):72-80.
Langerhans cell sarcoma. Am J Dermatopathol. 2006 Feb; 28(1):36-9.